Sunday, May 19, 2002

ASCO 2002 From the Booth
Maggie Hampshire, RN, BSN, OCN, Managing Editor, and Janet E. Finnegan, RN discuss OncoLink.


A Phase II Trial of Celecoxib (CX), Irinotecan (I), 5-Fluorouracil (5FU), and Leucovorin (LCV) in Patients with Unresectable or Metastatic Colorectal Cancer (CRC)
A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus
Cetuximab (C225) Plus Irinotecan (CPT-11) Plus Infusional 5FU/Folinic Acid (FA) is Safe and Active in Metastatic Colorectal Cancer (MCRC) that Expresses Epidermal Growth Factor Receptor (EGFR)
Cetuximab (IMC-C225) plus Weekly Irinotecan (CPT-11), Fluorouracil (5FU), and Leucovorin (LV) in Colorectal Cancer (CRC) that Expresses the Epidermal Growth Factor Receptor (EGFR)
Efficacy and Tolerability of Two Dosing Regimens of R115777 (Zarnestra), a Farnesyl Protein Transferase Inhibitor, in Patients with Advanced Breast Cancer
Final Results From A Phase II Trial Of Zd1839 ('Iressa') For Patients With Advanced Non-Small-Cell Lung Cancer (IDEAL 1)
Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG)
Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial
Incorporating Angiogenesis Inhibition with Bevacizumab (anti-VEGF) into Frontline Chemotherapy with Irinotecan (CPT-11), Fluorouracil and Leucovorin (FU/LV) for Advanced Colorectal Cancer (advCRC): A Toxicity Analysis of ECOG Study E2200
Inhibition of Epidermal Growth Factor/HER2 Receptor Signaling Using ZD1839
Long Term Survival Of Stage II And III Melanoma Patients With Respect To Serial Tyrosinase RT-PCR Testing In Peripheral Blood
Lymphatic Mapping And Sentinel Lymph Node Sampling In Breast Cancer: A Meta-Analysis
Multicenter Phase II Trial Of Paclitaxel (P), Ifosfamide (I), And Carboplatin (C) In Previously Untreated Extensive Stage Small Cell Lung Cancer (ES?SCLC)
Phase III Trail Comparing TAC (docetaxel, dosorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 Study
Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC)
Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- AND Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- And NOGGO-Intergroup Study
Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
The Role Of Sentinel Lymphadenectomy In Thin Cutaneous Melanomas